Latest & greatest articles for hydrochlorothiazide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrochlorothiazide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrochlorothiazide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrochlorothiazide

1. Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences?

Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences? Prescrire IN ENGLISH - Spotlight ''Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences?'', 1 July 2020 {1} {1} {1} | | > > > Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences? Queries and Comments In 2018, Prescrire reported the findings of two case-control studies that showed an increased risk of non-melanoma skin cancers in patients treated with hydrochlorothiazide, a first-choice antihypertensive drug. Does the evidence available in 2020 affect this drug's harm-benefit balance in hypertension? In practice : Inform and monitor

2020 Prescrire

2. Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. (Full text)

Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. Hypertension is a complex syndrome of multiple hemodynamic, neuroendocrine, and metabolic abnormalities. The goals of treatment in hypertension are to optimally control high blood pressure and to reduce associated cardiovascular morbidity and mortality using the most suitable therapy available. Hydrochlorothiazide (HCTZ) and chlorthalidone (CTLD) are with proven hypertensive effects. The topic of our meta

2020 Journal of human hypertension PubMed abstract

3. [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. (Abstract)

[Hydrochlorothiazide use and risk of skin cancers: A systematic review]. The risk of skin cancer induced by photosensiting drugs is well known. An association between hydrochlorothiazide use and skin cancer has been recently published in some epidemiological studies. A systematic review of case-control or prospectives cohorts showed an increased risk of cutaneous squamous cell carcinoma even if some confusing factors such as tobacco smoking was not analysed. Results are more conflicting

2020 La Revue de medecine interne

4. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis. (Full text)

Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis. Left ventricular hypertrophy develops in 36%-41% of hypertensive patients and independently predicts cardiovascular events and total mortality. Moreover, drug-induced reduction in left ventricular mass (LVM) correlates with improved prognosis. The optimal thiazide-type diuretic for reducing LVM is unknown (...) . Evidence regarding potency, cardiovascular events, sodium, and potassium suggested the hypothesis that "CHIP" diuretics (CHlorthalidone, Indapamide, and Potassium-sparing diuretic/hydrochlorothiazide [PSD/HCTZ]) would reduce LVM more than HCTZ. Systematic searches of five databases were conducted. Among the 38 randomized trials, a 1% reduction in systolic blood pressure (SBP) predicted a 1% reduction in LVM, P = 0.00001. CHIP-HCTZ differences in reducing LVM differed across trials (ie, heterogeneity

2019 Journal of clinical hypertension (Greenwich, Conn.) PubMed abstract

5. Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy?

Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? 1 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca November 25, 2019 (en français) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? Clinical Question: Does hydrochlorothiazide increase the risk of squamous cell carcinoma (SCC) of the skin? Bottom Line: Observational data suggest an association between hydrochlorothiazide and the risk of SCC. Causation has not been proven. Risk appears to consistently increase with dose and duration (example: 5 years of use increases risk 3-4 times). Baseline

2019 Tools for Practice

6. Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide. (Full text)

Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide. Sodium-glucose cotransporter (SGLT)-2 inhibitors lower clinic and ambulatory blood pressure (BP), possibly through their natriuretic action. However, it remains unclear whether this BP-lowering effect is dose dependent and different from that of low-dose hydrochlorothiazide. The purpose of this meta-analysis was to quantify the association (...) and diastolic BP.We identified seven RCTs (involving 2,381 participants) comparing SGLT-2 inhibitors with placebo. Of these, two RCTs included low-dose hydrochlorothiazide as active comparator. CFB in 24-h systolic BP between SGLT-2 inhibitor and placebo groups was -3.62 mmHg (95% CI -4.29, -2.94) and in diastolic BP was -1.70 mmHg (95% CI -2.13, -1.26). BP lowering with SGLT-2 inhibition was more potent during daytime than during nighttime. The CFB in ambulatory BP was comparable between low-dose and high

2019 Diabetes Care PubMed abstract

7. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use (Full text)

Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use - GOV.UK GOV.UK uses cookies to make the site simpler. Search Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need (...) of hydrochlorothiazide (see of data below) inform patients taking hydrochlorothiazide-containing products of the risk of non-melanoma skin cancer, particularly in long-term use, and advise them to regularly check for and report any new or changed skin lesions or moles reconsider the use of hydrochlorothiazide in patients who have had previous skin cancer examine all suspicious moles or skin lesions (potentially including histological examination of biopsies) advise patients to limit their exposure to sunlight and UV

2018 MHRA Drug Safety Update PubMed abstract

8. Hydrochlorothiazide

Hydrochlorothiazide Top results for hydrochlorothiazide - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 (...) or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydrochlorothiazide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

9. Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. (Abstract)

Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. Found in 36-41% of hypertension, elevated left ventricular mass (LVM) independently predicts cardiovascular events and total mortality. Conversely, drug-induced regression of LVM predicts improved outcomes. Previous studies have favored renin-angiotensin system inhibitors (RASIs) over other antihypertensives for reducing LVM (...) but ignored differences among thiazide-type diuretics. From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM.Systematic review yielded 12 relevant double-blind randomized trials. CHIPs were more closely associated with reduced LVM than HCTZ (P = 0.004), indicating that RASIs must be compared with each diuretic

2018 Journal of Hypertension

10. Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies. (Abstract)

Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies. The aim of this post-hoc analysis was to compare the results from randomized controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg).Data was pooled from 15 RCTs (N = 5542

2017 Current medical research and opinion

11. RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), renin inhibitor, alone or in combination with a diuretic

RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), renin inhibitor, alone or in combination with a diuretic Haute Autorité de Santé - RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), inhibiteur de la rénine, en association ou non à un diurétique Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments RASILEZ (...) (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), inhibiteur de la rénine, en association ou non à un diurétique Substance active (DCI) RASILEZ : aliskiren RASILEZ HCT : aliskiren/hydrochlorothiazide CARDIOLOGIE - Mise au point Nature de la demande Réévaluation SMR Avis de la CT du 14 décembre 2016 Intérêt clinique insuffisant dans le traitement de l’hypertension artérielle pour justifier le maintien du remboursement RASILEZ a l’AMM dans le traitement de l’hypertension artérielle essentielle chez

2017 Haute Autorite de sante

12. Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. (Full text)

Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. This study aimed to identify novel loci influencing the antihypertensive response to hydrochlorothiazide monotherapy. A genome-wide meta-analysis of blood pressure (BP) response to hydrochlorothiazide was performed in 1739 white hypertensives from 6 clinical trials within the International Consortium for Antihypertensive Pharmacogenomics Studies, making it the largest study (...) to date of its kind. No signals reached genome-wide significance (P<5×10-8), and the suggestive regions (P<10-5) were cross-validated in 2 black cohorts treated with hydrochlorothiazide. In addition, a gene-based analysis was performed on candidate genes with previous evidence of involvement in diuretic response, in BP regulation, or in hypertension susceptibility. Using the genome-wide meta-analysis approach, with validation in blacks, we identified 2 suggestive regulatory regions linked to gap

2016 Hypertension PubMed abstract

13. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. (Abstract)

Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Thiazide diuretics are still widely used as an initial therapy in essential hypertension, sometimes in both hypertensive and diabetic patients. However, the metabolic effects in type 2 diabetes treated with a thiazide diuretic have not been fully elucidated.Randomized controlled trials (RCTs) were identified from the electronic databases: the Cochrane Library (...) , MEDLINE, and PubMed web of knowledge. The trials compared the metabolic effects of hydrochlorothiazide (HCTZ) versus no- HCTZ hypertension treatment in type 2 diabetes.A total of 368 papers showed a match, in the keyword search. Upon screening the title, reading the abstract and the entire article, 13 parallel-design RCTs, described in 7 reports, involving 720 patients, showed fasting glucose (FG) (SMD = 0.27, 95% CI 0.11-0.43) and HbA1c (SMD = 1.09, 95% CI 0.47-1.72)significantly increased

2016 European review for medical and pharmacological sciences

14. Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Article Text Therapeutics/Prevention Randomised controlled trial In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Michael LeFevre Statistics from Altmetric.com Commentary on: Lonn EM , Bosch J , López

2016 Evidence-Based Medicine

15. [The optimal combination of captopril and hydrochlorothiazide in mild hypertension.]. (Abstract)

[The optimal combination of captopril and hydrochlorothiazide in mild hypertension.]. We have previously shown that in the treatment of mild to moderate hypertension little is gained by increasing the dose of hydrochlorothiazide (HCT) over 12.5 mg when combined with an ACE-inhibitor. An increase in dosing was associated with more numerous side effects. The present study was designed to explore the relative efficacy of 12.5 and 6.25 mg of HCT in combination with captopril (C).For the study 25

2015 Laeknabladid Controlled trial quality: uncertain

16. Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. (Full text)

Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. Hypokalemia is a recognized adverse effect of thiazide diuretic treatment. This phenomenon, which may impair insulin secretion, has been suggested to be a reason for the adverse effects on glucose metabolism associated with thiazide diuretic treatment of hypertension. However, the mechanisms underlying thiazide diuretic-induced hypokalemia (...) are not well understood. In an effort to identify genes or genomic regions associated with potassium response to hydrochlorothiazide, without a priori knowledge of biologic effects, we performed a genome-wide association study and a multiethnic meta-analysis in 718 European- and African-American hypertensive participants from two different pharmacogenetic studies. Single-nucleotide polymorphisms rs10845697 (Bayes factor=5.560) on chromosome 12, near to the HEME binding protein 1 gene, and rs11135740 (Bayes

2015 The pharmacogenomics journal PubMed abstract

17. Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. (Abstract)

Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. To compare the efficacy and safety of telmisartan 40 mg (T40) or 80 mg (T80) plus hydrochlorothiazide 12.5 mg (H12.5) single-pill combinations (SPCs) with telmisartan monotherapies, in a pooled analysis of patients with mild to moderate hypertension.Six phase 3, double-blind studies of 8 weeks' duration that assessed the T/H12.5 SPC and T40 or T80 monotherapy, were included

2014 Current medical research and opinion

18. Rasilez HCT (Aliskiren / hydrochlorothiazide) - essential hypertension

Rasilez HCT (Aliskiren / hydrochlorothiazide) - essential hypertension HAS - Medical, Economic and Public Health Assessment Division 1/15 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 4 December 2013 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 34009 392 151 6 7) RASILEZ HCT 150 mg/25 mg, film-coated tablets B/30 (CIP code: 34009 392 152 2 8) RASILEZ HCT 300 mg/12.5 mg, film-coated tablets B/30 (CIP code: 34009 392 153 9 6) RASILEZ HCT (...) 300 mg/25 mg, film-coated tablets B/30 (CIP code: 34009 392 154 5 7) Applicant: NOVARTIS PHARMA S.A.S. INN Aliskiren / hydrochlorothiazide ATC code (2008) C09XA52 (aliskiren and hydrochlorothiazide) Reason for the review Re-assessment of the actual benefit and the improvement in actual benefit, on the initiative of the Transparency Committee (in pursuance of Article R-163-21 of the Social Security Code). Renewal of inclusion Lists concerned National Health Insurance (French Social Security Code L

2014 Haute Autorite de sante

19. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension?

How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? View/ Open Date 2014-04 (...) Format Metadata Abstract Q. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? A. Both medications reduce theincidence of cardiovascular events in patients with hypertension, but chlorthalidone may confer additional cardiovascular risk reduction (strength of recommendation [SOR]: B, conflicting network meta-analysis and cohort studies). (No head-to-head studies of hydrochlorothiazide [HCTZ] and chlorthalidone have been done.) Serious hypokalemia and hyponatremia can

2014 Clinical Inquiries

20. Aliskiren/Amlodipine vs. Aliskiren/Hydrochlorothiazide in Hypertension: Indirect Meta-Analysis of Trials Comparing the Two Combinations vs. Monotherapy. (Full text)

Aliskiren/Amlodipine vs. Aliskiren/Hydrochlorothiazide in Hypertension: Indirect Meta-Analysis of Trials Comparing the Two Combinations vs. Monotherapy. Aliskiren, a direct renin inhibitor, is effective for reducing blood pressure (BP) in patients with hypertension when combined with amlodipine or hydrochlorothiazide (HCTZ). However, the efficacy and tolerability of the 2 combinations are unclear. We performed a meta-analysis of randomized controlled trials of aliskiren/amlodpine and aliskiren

2014 American journal of hypertension PubMed abstract